Schema-Root.org logo

 

  cross-referenced news and research resources about

 non-Hodgkin's lymphomas

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Tue. March 5, 2019

-
... have one of the covered conditions: bladder cancer, breast cancer, esophageal cancer, female infertility, hepatic steatosis, kidney cancer, leukemia, lung cancer, miscarriage, multiple myeloma, Myelodysplastic syndromes, neurobehavioral effects, non-Hodgkin's lymphoma, renal toxicity and scleroderma ...
The global non-hodgkin lymphoma therapeutics market has been estimated to reach USD 7.45 billion in 2023. The market is expected to register a CAGR of 7.4% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements.

SALT LAKE CITY — The chimeric antigen receptor T-cell therapy axicabtagene ciloleucel induced significant clinical benefit with manageable adverse events among patients with refractory aggressive non-Hodgkin lymphoma, according to long-term follow-up of the pivotal ZUMA-1 clinical trial presented at ...
A study to be presented at the BMT Tandem Meetings (February 21-25, 2018; Salt Lake City, UT) found no difference in overall survival (OS) for patients aged 55-64 years compared with those aged 65 years and older with non-Hodgkin lymphoma (NHL) who underwent allogeneic hematopoietic stem cell ...
Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma (NHL) showed that survival at 4 years following allogeneic hematopoietic cell transplantation (HCT) for patients age 65 years and older is comparable to patients age 55 to 64 years. The study demonstrates that age alone ...
OTTAWA -- Liberal MP Salma Zahid says she's taking a medical leave to be treated for non-Hodgkin's lymphoma. Zahid, who represents a Toronto-area riding, says she received the diagnosis in the last week. It followed weeks of intermittent pain that began after an overseas visit during the holidays.

Neelapu and colleagues demonstrated that more than half of patients with refractory, aggressive non-Hodgkin lymphoma remained alive at least 1 year after receiving a single infusion of anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences).
Direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection was well tolerated and appeared synergistic with chemotherapy of comorbid non-Hodgkin's lymphoma (NHL). The risk for NHL is increased with HCV infection, and successful treatment of HCV with pre-DAA era treatments has been ...
Oliver was diagnosed with non-Hodgkin's lymphoma at just six years old and the brothers found themselves in hospital beds next to one another, battling cancer together. Their mum revealed at first the family all just hoped it was some kind of error. Ms Redfearn, from Wakefield in West Yorkshire, said: “If ...
Although allogeneic hematopoietic stem cell transplantation (HCT) is a potentially curative therapy for patients with non-Hodgkin lymphoma (NHL), there is a lack of Medicare coverage, which has resulted in limited use among patients age 65 years or older. New research presented by investigators at the ...
It then shifted its focus to another treatment, this one for relapsed or refractory aggressive B cell non-Hodgkin lymphoma. In June, the biotech reported positive results from a phase 1 dose-finding study of the candidate, JCAR017. Juno is playing catch-up with Novartis and Kite Pharma—recently acquired by ...
Dr. Dunleavy: PMBCL is a very rare type of non-Hodgkin lymphoma. It makes up about 2% of all non-Hodgkin lymphomas and has historically been considered a subtype of diffuse large B-cell lymphoma, which is the most common type of non-Hodgkin lymphoma. But if you look at its biology closely, it's very ...
Scientists from Munich discovered a switch in Non-Hodgkin's lymphoma. December 6, 2017 - By Kurt Siggers. Most people are familiar with safety switches when it comes to different devices. However, not many of us are aware of safety switches in our body cells. While safety switches in electronic gadgets can help to avoid ...
These results can help to find new therapies against T cell Non-Hodgkin's lymphoma triggered by defective immune cells. In the body T cells are usually responsible for immediately detecting and killing cancer cells. However, problems can arise when a T cell itself develops a defect in its genome, the DNA.
That oncologist was Dr. Justin Markow. He delivered the news to Erskine that he had Non-Hodgkin Lymphoma. "It's difficult to broach that with patients but we do let them know that many patients can live for decades," Markow said. Still, it was bad news for a man who had just started retirement life. "Shock.
Results from one of the largest studies to date, which quantifies the five-year risk of new-onset Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) [excluding cutaneous T-cell lymphoma (CTCL)] and cutaneous T-cell lymphoma (CTCL) in patients with psoriasis, were presented at the Psoriasis: From ...
Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma – Pipeline Review, H2 2017, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape. Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a ...

Non-Hodgkin's Lymphoma (NHL)-Mechanism of action Insights, 2017″, report provides comprehensive insights of the ongoing therapeutic research and development across Non-Hodgkin's Lymphoma (NHL). The report provides a complete understanding of the pipeline activities covering all clinical, ...
Castaneda said hearing the diagnosis was difficult but he said he remains positive knowing non-Hodgkin's Lymphoma is one of the few ...
“Non-Hodgkin's Lymphoma (NHL) – Epidemiology Forecast To 2025” provides an overview of the epidemiology trends of Non-Hodgkin's Lymphoma (NHL) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of ...
... at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.
The report highlighted ASH abstracts on JCAR017, a non-Hodgkin lymphoma drug, showing promising efficacy and solid safety in r/r DLBCL, ...
Nordic Nanovector: Updated Results From Phase 1/2 Trial of Betalutin® in Non-Hodgkin Lymphoma to be Presented at ASH in December.
... the Food and Drug Administration approved Calquence, a new treatment for people with a rare and deadly form of non-Hodgkin lymphoma.
... amount of Nordic Nanovector's investigational therapy Betalutin that reaches tumor lesions in patients with non-Hodgkin's lymphoma (NHL).
Treatment with prolonged native E. coli asparaginase therapy for children with acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma ...
... local radiation) and in combination with MSD's anti-PD-1 agent Keytruda (pembrolizumab) for patients with follicular non-Hodgkin lymphoma.
Yescarta was granted FDA approval for use in adults with relapsed or refractory non-Hodgkin lymphoma. This is only the second CAR T-cell ...
The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adults with ...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly ...
A long-term follow-up study of immunotherapy with CAR T-cells in patients with B-cell non-Hodgkin's lymphoma with CD20-carrying B-cells ...
... for refractory aggressive non-Hodgkin lymphoma, and the therapy will also have the backing of biotech heavyweight Gilead moving forward.
Portland, OR -- (SBWIRE) -- 09/26/2017 -- Non-Hodgkin lymphoma (NHL) is a condition where abnormal lymphocytes are produced in the human body.
... is being combined with standard rituximab (Rituxan)-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma (NHL) in 2 ...
The two trials include patients with indolent non-Hodgkin's lymphoma of various types: follicular lymphoma; marginal zone lymphoma; small ...
Overview of “Global Non-Hodgkin Lymphoma Therapeutics Industry” Helps in providing scope and definations, Key Findings, Growth Drivers, ...
Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma, a cancer of the lymph system. The lymph system is part of the body's ...
HTF MI added a new research study in its database with title 'Non-Hodgkin Lymphoma – Pipeline Review, H2 2017' that includes detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions and important players/vendors such as 3SBio, ...
The Non Hodgkin Lymphoma market provides detailed analysis of Market Overview, Market Drivers, Opportunities, Potential Application.
ADC Therapeutics, a company specializing in the development of antibody drug conjugates (ADCs) for several cancer indications, has raised ...
Despite high efficacy, the $373,000 list price from the drug's manufacturer may preclude some patients from receiving axicabtagene ciloleucel.
Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Those three words bring one's world to a screeching halt, Columbus resident Sue Becker said. The 56-year-old certified oncology nurse said ...
Christopher Walsh can still remember the day he found a suspicious lump on his groin. He immediately went to the doctor to have the lump ...
Jordan was first diagnosed with non-Hodgkin lymphoma in 2009 and initially received treatment in California. She responded well to treatment ...
Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the ...
Non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes and is among the most common cancers, ...
MCL is an aggressive type of non-Hodgkin's lymphoma with poor prognosis. It accounts for approximately 3% to 6% of new non-Hodgkin's ...
... Medicines Agency (EMA) for axicabtagene ciloleucel (axi-cel) to treat 3 forms of non-Hodgkin lymphoma (NHL), Kite Pharma has announced.
University of Southampton scientists will trial a new experimental drug in combination with immunochemotherapy, in patients with the most ...


 

news and opinion


 


 


 


 


schema-root.org

   human
    diseases
     cancer
      lymphoma
        non‑hodgkin's

lymphomas:
        hodgkin's
        non‑hodgkin's